Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1<i>H</i>-pyrazol-4-yl)({[(2<i>S</i>)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework

John R. Doedens(Univera (United States)), Christopher A. Gabel(Community Health Systems - Lutheran Hospital), Christine Diamond(University of North Carolina at Chapel Hill), Andy Billinton(Chelmsford and Essex Hospital), MyTrang Nguyen(University of North Carolina at Chapel Hill), Beverly H. Koller(University of North Carolina at Chapel Hill), Heather Wescott(University of North Carolina at Chapel Hill), Pamela J. Smolak(Benjamin Franklin Institute of Technology), David Harrison(Chelmsford and Essex Hospital), Alan P. Watt(Essex Cardiothoracic Centre), Ken Schooley
ACS Pharmacology & Translational Science
April 18, 2024
Cited by 8


Related Papers